Blood biomarkers role in acute ischemic stroke patients: Higher is worse or better?

Immunity and Ageing

Volumn 9, Issue , 2012, Pages

  Kisialiou, Aliaksei ^a   Pelone, Giordana ^a   Carrizzo, Albino ^a   Grillea, Giovanni ^a   Trimarco, Valentina ^b   Marino, Marina ^b   Bartolo, Michelangelo ^a   De Nunzio, Alessandro M ^a   Grella, Rodolfo ^a   Landolfi, Alessandro ^a   Puca, Annibale ^c,d   Colonnese, Claudio ^a   Vecchione, Carmine ^a,d  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

Acute stroke; Biomarkers; Lesion size; Neuroimaging

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; CORRELATIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART RATE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SMOKING; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84868223316     PISSN: None     EISSN: 17424933     Source Type: Journal    
DOI: 10.1186/1742-4933-9-22     Document Type: Article

References (39)

1. Naess H, Tatlisumak T, Korv J. Stroke in the young 2012. Stroke 2012, 2012:656913.
2. Perls T, Kunkel LM, Puca AA. The genetics of exceptional human longevity. J Am Geriatr Soc 2002, 50:359-368. 10.1046/j.1532-5415.2002.49283.x, 12028221.
3. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003, 4:399-415.
4. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008, 371:1612-1623. 10.1016/S0140-6736(08)60694-7, 18468545.
5. del Zoppo GJ. Thrombolysis: from the experimental findings to the clinical practice. Cerebrovasc Dis 2004, 17(Suppl 1):144-152.
6. Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G. Inflammation in ischemic stroke subtypes. Curr Pharm Des 2012, 18:4289-4310. 10.2174/138161212802481200, 22390641.
7. Meng R, Ji X. Plasma biomarker and stroke. Cerebrovasc Dis 2011, 32:406. 10.1159/000331927, 21986385.
8. Montaner J, Perea-Gainza M, Delgado P, Ribo M, Chacon P, Rosell A, Quintana M, Palacios ME, Molina CA, Alvarez-Sabin J. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008, 39:2280-2287. 10.1161/STROKEAHA.107.505354, 18535284.
9. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, Welsh P, Green A, Andrews M, Sandercock P. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 2012, 43:86-91. 10.1161/STROKEAHA.111.634089, 22020034.
10. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, Hurn P, Liebeskind DS, Nogueira RG, Saver JL. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke 2011, 42:2645-2650. 10.1161/STROKEAHA.111.618850, 21852620.
11. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 2010, 87:779-789. 10.1189/jlb.1109766, 2858674, 20130219.
12. Brait VH, Jackman KA, Walduck AK, Selemidis S, Diep H, Mast AE, Guida E, Broughton BR, Drummond GR, Sobey CG. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J Cereb Blood Flow Metab 2010, 30:1306-1317. 10.1038/jcbfm.2010.14, 2949221, 20145655.
13. Chamorro A, Vila N, Ascaso C, Saiz A, Montalvo J, Alonso P, Tolosa E. Early prediction of stroke severity. Role of the erythrocyte sedimentation rate. Stroke 1995, 26:573-576. 10.1161/01.STR.26.4.573, 7709399.
14. Chamorro A. Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis 2004, 17(Suppl 3):1-5.
15. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012, 34:43-62. 10.1007/s00281-011-0290-8, 22037947.
16. Rautou PE, Vion AC, Amabile N, Chironi G, Simon A, Tedgui A, Boulanger CM. Microparticles, vascular function, and atherothrombosis. Circ Res 2011, 109:593-606. 10.1161/CIRCRESAHA.110.233163, 21852557.
17. Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg 1997, 87:595-601. 10.3171/jns.1997.87.4.0595, 9322848.
18. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001, 32:553-560. 10.1161/01.STR.32.2.553, 11157196.
19. Lu HT, Zhao JG, Li MH, Li YD. Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model. Brain Res 2012, 1438:75-84.
20. Martineau J, Bauer JD, Isenring E, Cohen S. Malnutrition determined by the patient-generated subjective global assessment is associated with poor outcomes in acute stroke patients. Clin Nutr 2005, 24:1073-1077. 10.1016/j.clnu.2005.08.010, 16213064.
21. Idicula TT, Waje-Andreassen U, Brogger J, Naess H, Thomassen L. Serum albumin in ischemic stroke patients: the higher the better. The Bergen Stroke Study. Cerebrovasc Dis 2009, 28:13-17. 10.1159/000215938, 19420917.
22. Abboud H, Labreuche J, Meseguer E, Lavallee PC, Simon O, Olivot JM, Mazighi M, Dehoux M, Benessiano J, Steg PG, Amarenco P. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007, 23:216-220. 10.1159/000097644, 17143006.
23. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308. 10.1001/jama.298.3.299, 17635890.
24. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008, 300:2142-2152. 10.1001/jama.2008.621, 19001625.
25. Luitse MJ, Biessels GJ, Rutten GE, Kappelle LJ. Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol 2012, 11:261-271. 10.1016/S1474-4422(12)70005-4, 22341034.
26. Prajapati KD, Sharma SS, Roy N. Current perspectives on potential role of albumin in neuroprotection. Rev Neurosci 2011, 22:355-363.
27. Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, Armitage J, Collins R. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012, 125:2469-2478. 10.1161/CIRCULATIONAHA.111.073684, 22539783.
28. Munshi A, Babu MS, Kaul S, Rajeshwar K, Balakrishna N, Jyothy A. Association of LPL gene variant and LDL, HDL, VLDL cholesterol and triglyceride levels with ischemic stroke and its subtypes. J Neurol Sci 2012, 318:51-54. 10.1016/j.jns.2012.04.006, 22541364.
29. Geeganage CM, Diener HC, Algra A, Chen C, Topol EJ, Dengler R, Markus HS, Bath MW, Bath PM. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke J Cerebr Circ 2012, 43:1058-1066.
30. Nayak AR, Kashyap RS, Kabra D, Deoras P, Purohit HJ, Taori GM, Daginawala HF. Evaluation of routinely performed hematological and biochemical parameters for the prognosis of acute ischemic stroke patients. Neurol Sci 2011, 32:855-860. 10.1007/s10072-011-0718-x, 21863274.
31. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799-1809.
32. Turaj W, Slowik A, Dziedzic T, Pulyk R, Adamski M, Strojny J, Szczudlik A. Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci 2006, 246:13-19. 10.1016/j.jns.2006.01.020, 16650435.
33. Kang DW, Chalela JA, Ezzeddine MA, Warach S. Association of ischemic lesion patterns on early diffusion-weighted imaging with TOAST stroke subtypes. Arch Neurol 2003, 60:1730-1734. 10.1001/archneur.60.12.1730, 14676047.
34. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, Kaczorowski J. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ 2011, 342:d286. 10.1136/bmj.d286, 3034423, 21300709.
35. Myers MG, Godwin M. Automated office blood pressure. Can J Cardiol 2012, 28:341-346. 10.1016/j.cjca.2011.09.004, 22265230.
36. Rivers CS, Wardlaw JM, Armitage PA, Bastin ME, Hand PJ, Dennis MS. Acute ischemic stroke lesion measurement on diffusion-weighted imaging-important considerations in designing acute stroke trials with magnetic resonance imaging. J Stroke Cerebrovasc Dis 2007, 16:64-70. 10.1016/j.jstrokecerebrovasdis.2006.11.003, 17689396.
37. Buck BH, Liebeskind DS, Saver JL, Bang OY, Yun SW, Starkman S, Ali LK, Kim D, Villablanca JP, Salamon N, et al. Early neutrophilia is associated with volume of ischemic tissue in acute stroke. Stroke 2008, 39:355-360. 10.1161/STROKEAHA.107.490128, 18162626.
38. Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P. Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. Br J Clin Pharmacol 2012, 74:230-240. 10.1111/j.1365-2125.2012.04212.x, 22320313.
39. Fonarow GC, Pan W, Saver JL, Smith EE, Reeves MJ, Broderick JP, Kleindorfer DO, Sacco RL, Olson DM, Hernandez AF, et al. Comparison of 30-day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity. JAMA 2012, 308:257-264. 10.1001/jama.2012.7870, 22797643.